Patent SG-11201810454Y-A (SG)
Title: Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
Inventor: FARSACI BENEDETTO
IPC: C07K16/28
Filed: 2017-06-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER (19) World Intellectual Property Organization International Bureau (43) International Publication Date ......0\" 07 December 2017 (07.12.2017) WIP0 I PCT THE PATENT COOPERATION TREATY (PCT) IIi v (10) International Publication Number WO 2017/210473 Al (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) International Application Number: (74) PCT/US2017/035521 International Filing Date: 01 June 2017 (01.06.2017) (81) English Publication Language: English Priority Data: 62/344,866 02 June 2016 (02.06.2016) US 62/382,839 02 September 2016 (02.09.2016) US Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Rt. 206 & Province Line Road, Princeton, New Jersey 08543 (US). SEATTLE GENETICS, INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (84) (US). Inventors: FARSACI, Benedetto; Rt. 206 & Province Line Road, Princeton, New Jersey 08543 (US). JOSEPHSON, Neil; c/o Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). CAO, Antho- ny; 23707 NE 25th Way, Sammamish, Washington 98074 (US). HEISER, Ryan; 1032 116th Ave SE, Lake Stevens, Washington 98258 (US). Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = (54) Title: USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN LYMPHOMA FIG. 1 = TREATMENT - = = = = = a a a a a a a,g a a a a m 1 a a a a A A M A M A A A A a A a a a a a a a a a a a a a a a a a a a a a a a 0 a 3 A A * aaa = = © 1-1 N IN 1 -1 (57) N Hodgkin's lymphoma in combination with - an anti CD30 antibody, such as brentuximab vedotin. O nivolumab, : The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory [Continued on next page] WO 2017/210473 Al MIDEDIMOHNIIMMEMIMANHOHINDEVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))